Oppenheimer analyst Andreas Argyrides assumed coverage of Dyne Therapeutics (DYN) with an Outperform rating with a price target of $34, down from $60, after the company reported its Q1 and highlighted progress across its DM1 and Duchenne muscular dystrophy programs. In the Phase 1/2 ACHIEVE trial of DYNE-101 in DM1, following the recent compelling data, the firm is encouraged to see the registrational expansion cohort staying on track for readout in the first half of 2026. Management highlighted its recent participation in a CDER Type C held in May 2025 for DYNE-101 in DM1, and plans to provide a regulatory update following receipt of meeting minutes. In the Phase 1/2 DELIVER trial of DYNE-251 in DMD, the registrational expansion cohort readout remains expected in late 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics initiated with an Outperform at Evercore ISI
- Optimistic Buy Rating for Dyne Therapeutics Driven by Promising Clinical Progress and Regulatory Advancements
- Dyne Therapeutics price target lowered to $38 from $46 at H.C. Wainwright
- Dyne Therapeutics: Strategic Advancements and Strong Financials Support Buy Rating
- Dyne Therapeutics reports Q1 EPS (81c), consensus (84c)